McKesson Ventures
  • Portfolio
  • News
  • Team
  • About Us
    • Our Approach
    • About McKesson
    • Contact Us

GRAIL Announces First Health System to Offer Galleri, Novel Multi-Cancer Early Detection Blood Test

by McKesson Ventures | Mar 2, 2021 | Press Releases

GRAIL today announced a partnership with the health system Providence to offer Galleri, GRAIL’s multi-cancer early detection blood test. Providence, based in Renton, Wash., will offer Galleri as a complement to recommended single cancer screening tests. Providence...

Grail Signs on Quest Diagnostics to Provide Phlebotomy for Cancer Detection Test

by McKesson Ventures | Feb 23, 2021 | Portfolio News

GRAIL has entered an agreement with Quest Diagnostics to provide phlebotomy services in support of its multi-cancer early detection blood test. The test, called Galleri, is expected to go to market in the second quarter after its PATHFINDER multi-site interventional...

GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease

by McKesson Ventures | Jan 11, 2021 | Press Releases

GRAIL today announced a collaboration with global biopharmaceutical companies Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate GRAIL’s methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and...

GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test

by McKesson Ventures | Jan 11, 2021 | Press Releases

GRAIL has confirmed that it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021. In December 2020, GRAIL completed the enrollment of PATHFINDER, a prospective, 6,600-participant multi-site interventional study...

Illumina to Acquire GRAIL to Launch New Era of Cancer Detection

by McKesson Ventures | Sep 28, 2020 | Portfolio News

GRAIL and Illumina have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. In addition, GRAIL stockholders will receive future payments representing a tiered...
Page 2 of 10«12345...10...»Last »

Recent Posts

  • Samsung Electronics Acquires Xealth, Bridging The Gap Between Wellness and Medical Care
  • CoverMyMeds Announces Acquisition of Companies RxLightning and FastAuth
  • Komodo Health Partners With Nasdaq to Deliver First Integrated Healthcare-Specialized Data Insights to the Financial Services Industry
  • Atropos Health Expands Oncology MultiModal Network in the Atropos Evidence Network with Addition of Ontada
  • Lumata Health Secures $23 Million Series B to Expand Access and Adherence to Vision-Saving Care
McKesson Ventures
One Post Street, 21st Floor
San Francisco, CA 94104
USA

Contact Us

Cookie Settings

In the News

Lumata Health Secures $23 Million Series B to Expand Access and Adherence to Vision-Saving Care

Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials

Lynx Closes $27 Million Oversubscribed Series A, Aims to Revolutionize Healthcare Payments and Administration

HarmonyCares Announces 2023 Results for its High Needs REACH ACO

©2025 McKesson Ventures | Privacy Notice | Disclaimer
  • Follow
  • Follow